drugset
drugset / Trial / NCT01927055

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

NCT01927055 ↗

Phase 3 Terminated 61 enrolled Chelsea Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

Evaluate the clinical efficacy and safety of droxidopa versus placebo over a 17 week (maximum) treatment period in patients with symptomatic NOH.

Timeline

Start
2013-11
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Droxidopa Small molecule 100 mg —
Comparator Droxidopa Small molecule 200 mg —
Comparator Droxidopa Small molecule 300 mg —

Indications

Parkinson disease disorder of catecholamine synthesis orthostatic hypotension pure autonomic failure